<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0319</journal-id>
<journal-title><![CDATA[Medicas UIS]]></journal-title>
<abbrev-journal-title><![CDATA[Medicas UIS]]></abbrev-journal-title>
<issn>0121-0319</issn>
<publisher>
<publisher-name><![CDATA[Universidad Industrial de Santander]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-03192020000100053</article-id>
<article-id pub-id-type="doi">10.18273/revmed.v33n1-2020006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Mercado del Cannabis medicinal en Colombia: una oportunidad para el sector salud que requiere lineamientos estratégicos del gobierno nacional y la academia]]></article-title>
<article-title xml:lang="en"><![CDATA[Medical Marijuana market in Colombia: an opportunity for the health sector that requires strategic guidelines from the national government]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ledezma-Morales]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Adriana Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia Grupo de Investigación Promoción y Prevención Farmacéutica ]]></institution>
<addr-line><![CDATA[Medellín Antioquia]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín Antioquia]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín Antioquia]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2020</year>
</pub-date>
<volume>33</volume>
<numero>1</numero>
<fpage>53</fpage>
<lpage>58</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-03192020000100053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-03192020000100053&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-03192020000100053&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los resultados de las investigaciones sobre cannabis medicinal han traído a las mesas de gobierno discusiones sobre su potencial terapéutico y las medidas a tomar para controlar su producción, comercialización y utilización. En Colombia, desde el 2017, el mercado del cannabis medicinal se encuentra regulado; sin embargo, existen brechas entre la norma, disponibilidad y acceso de los pacientes a productos farmacéuticos con derivados del cannabis, aprobados por el ente regulatorio y que cumplan con los estándares de calidad. Desde esta perspectiva, se considera necesario que el gobierno nacional lidere, en coordinación con la academia y el sector productivo, el desarrollo de preparados farmacéuticos a base de cannabis; además de establecer e implementar medidas estratégicas y concertadas, orientadas a mejorar el acceso y la utilización adecuada de los productos farmacéuticos de cannabis medicinal, en especial para los casos en los que se pueda establecer una clara relación riesgo/beneficio. Con ello, se contribuye a mejorar las condiciones de salud de pacientes que se pueden beneficiar de estas opciones, al igual que al desarrollo y consolidación de un sector promisorio para el país. MÉD. UIS.2020;33(1):53-8.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The results of medical marijuana research have brought to the government tables discussions about their therapeutic potential and the measures to be taken to control their production, commercialization and use. In Colombia, since 2017, the medical cannabis market is regulated; however, there are gaps between the laws, availability and the access of patients to pharmaceutical products with cannabis derivatives approved by the regulatory entity and that comply with the standards of quality. From this perspective, it is necessary for the national government to lead, in coordination with the academy and the productive sector, the development of pharmaceutical preparations based on cannabis and to establish and implement strategic and concerted measures, aimed to improve access and proper use of medical marijuana pharmaceutical products, mainly for cases in which a clear risk/benefit relationship can be established. This would help to improve the health conditions of patients who can get benefits from these options, as well as the development and consolidation of a promising sector for the country. MÉD.UIS.2020;33(1):53-8.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Marihuana Medicinal]]></kwd>
<kwd lng="es"><![CDATA[Cannabinoides]]></kwd>
<kwd lng="es"><![CDATA[Legislación de Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Política de Salud.]]></kwd>
<kwd lng="en"><![CDATA[Medical Marijuana]]></kwd>
<kwd lng="en"><![CDATA[Cannabinoids]]></kwd>
<kwd lng="en"><![CDATA[Health Policy.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pacher]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kogan]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond THC and Endocannabinoids]]></article-title>
<source><![CDATA[Annu Rev Pharmacol Toxicol]]></source>
<year>2020</year>
<volume>60</volume>
<page-range>637-59</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pertwee]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging strategies for exploiting cannabinoid receptor agonists as medicines]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2009</year>
<volume>156</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>397-411</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bridgeman]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Abazia]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicinal Cannabis History, Pharmacology, And Implications for the Acute Care Setting]]></article-title>
<source><![CDATA[P T Peer-Rev J Formul Manag]]></source>
<year>2017</year>
<volume>42</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>180-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Resstel]]></surname>
<given-names><![CDATA[LBM]]></given-names>
</name>
<name>
<surname><![CDATA[Tavares]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Lisboa]]></surname>
<given-names><![CDATA[SFS]]></given-names>
</name>
<name>
<surname><![CDATA[Joca]]></surname>
<given-names><![CDATA[SRL]]></given-names>
</name>
<name>
<surname><![CDATA[Corrêa]]></surname>
<given-names><![CDATA[FMA]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[5-HT1A receptors are involved in the cannabidiolinduced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2009</year>
<volume>156</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>181-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schier AR de]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro NP de]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Silva AC de]]></surname>
<given-names><![CDATA[O e]]></given-names>
</name>
<name>
<surname><![CDATA[Hallak]]></surname>
<given-names><![CDATA[JEC]]></given-names>
</name>
<name>
<surname><![CDATA[Crippa]]></surname>
<given-names><![CDATA[JAS]]></given-names>
</name>
<name>
<surname><![CDATA[Nardi]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug]]></article-title>
<source><![CDATA[Rev Bras Psiquiatr Sao Paulo Braz 1999]]></source>
<year>2012</year>
<volume>34</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S104-10</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Connell]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Gloss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids in treatmentresistant epilepsy A review]]></article-title>
<source><![CDATA[Epilepsy Behav EB]]></source>
<year>2017</year>
<volume>70</volume>
<numero>B</numero>
<issue>B</issue>
<page-range>341-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whiting]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Deshpande]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Di Nisio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids for Medical Use A Systematic Review and Meta-analysis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>313</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2456-73</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin-Santos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Crippa J, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, et al Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers]]></article-title>
<collab>A</collab>
<source><![CDATA[Curr Pharm Des]]></source>
<year>2012</year>
<volume>18</volume>
<numero>32</numero>
<issue>32</issue>
<page-range>4966-79</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Decreto 613 de 2017]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Furnas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nabilone an effective antiemetic in patients receiving cancer chemotherapy]]></article-title>
<source><![CDATA[J Clin Pharmacol.]]></source>
<year>1981</year>
<volume>21</volume>
<numero>S1</numero>
<issue>S1</issue>
<page-range>64S-9S</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zajicek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vickery]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nunn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study) multicentre randomised placebo-controlled trial]]></article-title>
<source><![CDATA[Lancet Lond Engl.]]></source>
<year>2003</year>
<volume>362</volume>
<numero>9395</numero>
<issue>9395</issue>
<page-range>1517-26</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Laux]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nabbout]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2017</year>
<volume>376</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2011-20</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>Food and Drug Administration</collab>
<source><![CDATA[Cesamet Label]]></source>
<year>2006</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>Food and Drug Administration</collab>
<source><![CDATA[Marinol. Highlights of prescribing information]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Food and Drug Administration</collab>
<source><![CDATA[Epidiolex. Highlights of prescribing information]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[European Medicines Agency]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios.</collab>
<source><![CDATA[SATIVEX]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Health Canada. Fact Sheet</collab>
<source><![CDATA[SATIVEX]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>Agencia Nacional de Vigilancia Sanitaria-Brasil</collab>
<source><![CDATA[Mevatil]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos</collab>
<source><![CDATA[Consulta Registros Sanitarios]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos</collab>
<source><![CDATA[Listado de plantas medicinales]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Australian Government Department of Health Therapeutic Goods</collab>
<source><![CDATA[Guidance for the use of medicinal cannabis for the prevention or management of nausea and vomiting in Australia]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makary]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Parmar]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Mims]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Khanfar]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain]]></article-title>
<source><![CDATA[J Pain Palliat Care Pharmacother]]></source>
<year>2018</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>216-25</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos</collab>
<source><![CDATA[Guía para las visitas de buenas prácticas de elaboración de preparaciones magistrales a base de cannabis]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución 315 de 2020]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>Ministério da Saúde/Agência Nacional de Vigilância Sanitária/Diretoria Colegiada</collab>
<source><![CDATA[Resolução da diretoria colegiada - RDC No 327, de 9 de dezembro de 2019. Dispõe sobre os procedimentos para a concessão da Autorização Sanitária para a fabricação e a importação, bem como estabelece requisitos para a comercialização, prescrição, a dispensação, o monitoramento e a fiscalização de produtos de Cannabis para fins medicinais, e dá outras providências]]></source>
<year>2019</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
